Despite the severity of TNBC, only two specific drugs have been approved by the FDA to treat it—one of them is only approved for metastatic patients. TNBC is the only breast cancer subtype that does not have any drugs to prevent recurrence. Of the drugs that are available and FDA approved, none had clinical trial demographics that reflected the actual demographics of TNBC patients. Instead, most TNBC treatments are trialed on white women with early-stage breast cancer who, on average, are 55 years old.⁴

A treatment that works for an older, earlier stage white patient may not work the same for our bodies. The truth is, we can’t know without more research and data. In order to test how drugs work on Black bodies and keep Black Blessties from dying at higher rates, we need more Black women in clinical trials, especially TNBC clinical trials.

When you consider enrolling in a clinical trial, you’re not only investing in the most cutting-edge treatments for yourself, but you also take the first step towards helping to develop better TNBC treatments for all Black women.

When we tri(al), we are counted. When we tri(al), we make a difference in triple negative breast cancer research.
 
 
1 https://pubmed.ncbi.nlm.nih.gov/27583878/
2  American Cancer Society
3 https://onlinelibrary.wiley.com/doi/10.1002/cam4.4158
4. 2019 Drug Trials Snapshots Summary Report. U.S. Food & Drug Administration.  https://www.fda.gov/media/135337/download.